Pioneering designs for recombinant coagulation factors

Thrombosis Research

Volumn 128, Issue SUPPL. 1, 2011, Pages S9-

  Schulte, Stefan ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Albumin fusion protein; Factor IX; Factor VII; Factor VIII; Half life; Hemophilia

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CSL 627; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT SINGLE CHAIN FACTOR VIII PROTEIN; UNCLASSIFIED DRUG;

CLINICAL EVALUATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84855413310     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(12)70003-8     Document Type: Article

References (33)

1. Pipe S. Visions in haemophilia care. Thromb Res 2009;124(Suppl. 2):S2-5.
2. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008;122:S14-9.
3. Byrne B, Donohoe GG, O'Kennedy R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov Today 2007;12:319-26. (Pubitemid 46467485)
4. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009;24:318-32.
5. Gao Z, Bai G, Chen J, Zhang Q, Pan P, Bai F, Geng P. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci Biotechnol Biochem 2009;73:688-94.
6. Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007;25:1411-9. (Pubitemid 350233139)
7. Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009;23:93-109.
8. Schmidt SR. Fusion-proteins as biopharmaceuticals - applications and challenges. Curr Opin Drug Discov Devel 2009;12:284-95.
9. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006;27:343-8. (Pubitemid 43963476)
10. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002;19:569-77. (Pubitemid 34553662)
11. Metzner JH, Wiemer T, Schulte S. Half-life extension by fusion to recombinant albumin. In: Kontermann R, ed. Therapeutic proteins: strategies to modulate their plasma half-life. Weinheim: Wiley-VCH Verlag; in press.
12. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005;54:251-8. (Pubitemid 40105120)
13. Syed S, Schuyler PD, Kulczycky M, Sheffield WP. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997;89:3243-52. (Pubitemid 27229809)
14. Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, Rodriquez-Torres M, et al. Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C. J Hepatol 2009;50(Suppl. 1):S378[Abstract 1042].
15. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, et al. Albinterfeon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010:139:1257-66.
16. Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 2005;54:535-47.
17. Yao Z, Dai W, Perry J, Brechbiel MW, Sung C. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol Immunother 2004;53:404-10. (Pubitemid 38657253)
18. Huang YJ, Lundy PM, Lazaris A, Huang Y, Baldassarre H, Wang B, et al. Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol 2008;8:50.
19. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost. 2000;26:385-91.
20. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-8. (Pubitemid 28556692)
21. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-8. (Pubitemid 28521721)
22. Kronthaler U, Schmidbauer S, Liebing U, Lang W, Metzner HJ, Weimer T, Schulte S. Prolonged half-life of recombinant factor VIIa fusion protein - single dose study in rabbits. J Thromb Haemost 2009;7(Suppl. 2):[Abstract PP-TT-561].
23. Schulte S, Weimer T, Wormsbächer W, Kronthaler U, Groener A, Lang W, Liebing U. Prolonged in vivo half-life of FVIIa by fusion to albumin. Blood 2007;110. Abstr. 3142.
24. Weimer T, Wormsbächer W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008;99:659-67. (Pubitemid 351694221)
25. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA; Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002;42:190-7.
26. White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997;78:261-5. (Pubitemid 27289251)
27. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001;7:133-9. (Pubitemid 32243794)
28. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009;102:634-44.
29. Schulte S. Half-life extension through albumin fusion technologies. Thromb Res 2009;124:S6-8.
30. Sheffield WP, Mamdani A, Hortelano G, Gataiance S, Eltringham-Smith L, Begbie ME, et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004;126:565-73. (Pubitemid 39093100)
31. Nolte MW, Nichols T, Zollner S, Mueller-Cohrs J, Pragst I, Dickneite G. Improved kinetics of rIX-FP, a recombinant fusion protein linking coagulation factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. J Thromb Haemost 2011;9(Suppl. 2): 220[Abstract P-MO-514].
32. McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, et al. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 2002;87:824-30. (Pubitemid 34516609)
33. Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007;109:610-2. (Pubitemid 46105959)